Target intelligence / Profile preview

Indirect pathway of the basal ganglia (Indirect pathway)

Target
Indirect pathway
Molecular classification
Other (Neural circuit)
01

Overview

The indirect pathway of the basal ganglia is a multi-synaptic neural circuit that plays a critical role in motor control by inhibiting movement (StatPearls, 2023). It begins with the projection of GABAergic medium spiny neurons from the striatum to the globus pallidus externa (GPe); these neurons specifically express dopamine D2 receptors (Nature Reviews Neuroscience, 2010). The circuit continues from the GPe to the subthalamic nucleus (STN), which then provides excitatory glutamatergic input to the globus pallidus interna (GPi) and substantia nigra pars reticulata (SNr). Increased activity in this pathway leads to greater inhibition of the thalamus, thereby reducing excitatory drive to the motor cortex and suppressing movement (Wikipedia, 2024). In Parkinson's disease, the depletion of dopamine leads to the disinhibition and overactivity of the indirect pathway, contributing to symptoms like bradykinesia and rigidity (Movement Disorders, 2015). Conversely, underactivity of this pathway is associated with hyperkinetic disorders such as Huntington's disease. Therapeutic strategies often involve dopamine D2 receptor agonists to reduce the pathway's activity or surgical interventions like Deep Brain Stimulation (DBS) targeting the STN to modulate the circuit's output. Pharmacological agents like antipsychotics act as D2 antagonists, which can inadvertently increase indirect pathway activity, leading to extrapyramidal side effects.

Other names
Striatopallidal pathwayD2-mediated pathwayIndirect motor loop
02

Mechanism of action

Modulation of dopamine D2 receptors on striatal medium spiny neurons to regulate the inhibitory output of the basal ganglia circuit, thereby influencing motor suppression.

03

Biological functions

Motor controlInhibition of movementBehavioral flexibilityCognitive control
04

Disease associations

Parkinson's diseaseHuntington's diseaseDystoniaSchizophreniaTourette syndrome
05

Safety considerations

Extrapyramidal symptomsTardive dyskinesiaDyskinesiaImpulse control disordersNeuroleptic malignant syndrome
06

Interacting drugs

Haloperidol

7 more in the full profile.

07

Biomarkers

Beta-band oscillations (13-30 Hz) in the subthalamic nucleusStriatal D2 receptor occupancyDopamine transporter (DAT) density

Beyond the preview

Go deeper on Indirect pathway of the basal ganglia (Indirect pathway).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indirect pathway of the basal ganglia (Indirect pathway).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call